Clinical impact of hepatitis B and C virus envelope glycoproteins.

about

Status of hepatitis C virus vaccination: Recent update Applications of human hepatitis B virus preS domain in bio- and nanotechnology.Tupaia belangeri as an experimental animal model for viral infection

P2860

Q26774612-FD8EBF30-5F81-411F-AAA4-B974B878C57F Q27693188-AB160533-D79F-4CEB-9493-8DEB4C07F767 Q28651439-A7523EFA-0CFA-40C0-882A-0C17946DD60A

P2860

Clinical impact of hepatitis B and C virus envelope glycoproteins.

Item

http://www.wikidata.org/entity/Q38083515

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Clinical impact of hepatitis B and C virus envelope glycoproteins.

@en

type

Item

label

Clinical impact of hepatitis B and C virus envelope glycoproteins.

@en

prefLabel

Clinical impact of hepatitis B and C virus envelope glycoproteins.

@en

P1476

Clinical impact of hepatitis B and C virus envelope glycoproteins.

@en

P2093

Aurélie Velay

http://www.w3.org/2001/XMLSchema#string

Evelyne Schvoerer

http://www.w3.org/2001/XMLSchema#string

Hélène Jeulin

http://www.w3.org/2001/XMLSchema#string

John Murray

http://www.w3.org/2001/XMLSchema#string

P2860

Viral and cellular determinants involved in hepadnaviral entry

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Persistent Hepatitis C Virus Infection In Vitro: Coevolution of Virus and Host

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

Significance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral Outcome

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies

Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant

P304

654-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V19.I5.654

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235690267

http://www.w3.org/2001/XMLSchema#string

P698

23429668

http://www.w3.org/2001/XMLSchema#string

P932

3574591

http://www.w3.org/2001/XMLSchema#string

Clinical impact of hepatitis B and C virus envelope glycoproteins.

about

P2860

P2860

Clinical impact of hepatitis B and C virus envelope glycoproteins.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932